Low-dose metronomic chemotherapy: A systematic literature analysis

European Journal of Cancer

Volumn 49, Issue 16, 2013, Pages 3387-3395

  Lien, K ^a   Georgsdottir, S ^a   Sivanathan, L ^a   Chan, K ^a   Emmenegger, U ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti angiogenesis; Low dose chemotherapy; Metronomic chemotherapy; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXIFLURIDINE; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PREDNISONE; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; TROFOSFAMIDE; UFT; VINBLASTINE;

ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; COLITIS; DATA BASE; DIARRHEA; EMBASE; ENDOTHELIAL PROGENITOR CELL; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LOW DOSE METRONOMIC CHEMOTHERAPY; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MEDLINE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; POPULATION SIZE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-ANGIOGENESIS; LOW-DOSE CHEMOTHERAPY; METRONOMIC CHEMOTHERAPY; SYSTEMATIC REVIEW;

ADMINISTRATION, METRONOMIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885179445     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.038     Document Type: Article

References (37)

1. R.S. Kerbel, and B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nat Rev Cancer 4 6 2004 423 436 [PubMed PMID: 15170445. Epub 2004/06/02.eng]
2. D. Hanahan, G. Bergers, and E. Bergsland Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice J Clin Invest 105 8 2000 1045 1047 [PubMed PMID: 10772648. Pubmed Central PMCID: PMC300842. Epub 2000/04/20.eng]
3. T. Browder, C.E. Butterfield, and B.M. Kräling Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 7 2000 1878 1886
4. G. Klement, S. Baruchel, and J. Rak Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 105 8 2000 R15 R24 [PubMed PMID: 10772661. Pubmed Central PMCID: PMC517491. Epub 2000/04/20.eng]
5. E. Pasquier, M. Kavallaris, and N. Andre Metronomic chemotherapy: new rationale for new directions Nat Rev Clin Oncol 7 8 2010 455 465 [PubMed PMID: 20531380. Epub 2010/06/10.eng]
6. U. Emmenegger, G. Francia, Y. Shaked, and R.S. Kerbel Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer Recent Results Cancer Res 180 2010 165 183 [PubMed PMID: 20033383. Epub 2009/12/25.eng]
7. C. Folkins, S. Man, P. Xu, Y. Shaked, D.J. Hicklin, and R.S. Kerbel Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors Cancer Res 67 8 2007 3560 3564 [PubMed PMID: 17440065. Epub 2007/04/19.eng]
8. I. Martin-Padura, P. Marighetti, and A. Agliano Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts Lab Invest 92 7 2012 952 966 [PubMed PMID: 22546866. Epub 2012/05/02.eng]
9. K. Mross, and S. Steinbild Metronomic anti-cancer therapy - an ongoing treatment option for advanced cancer patients J Cancer Ther Res 1 1 2012 32
10. A. Fontana, A. Falcone, L. Derosa, T. Di Desidero, R. Danesi, and G. Bocci Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients? Drugs Aging 27 9 2010 689 696 [PubMed PMID: 20809660. Epub 2010/09/03.eng]
11. G. Bocci, M. Tuccori, and U. Emmenegger Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation Ann Oncol 16 8 2005 1243 1252 [PubMed PMID: 15905308. Epub 2005/05/21.eng]
12. E. Collova, F. Sebastiani, and E. De Matteis Use of metronomic chemotherapy in oncology: results from a national Italian survey Tumori 97 4 2011 454 458 [PubMed PMID: 21989433. Epub 2011/10/13.eng]
13. H. Kato, Y. Ichinose, and M. Ohta A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung N Engl J Med. 350 17 2004 1713 1721 [PubMed PMID: 15102997. Epub 2004/04/23.eng]
14. T. Watanabe, M. Sano, and S. Takashima Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: national surgical adjuvant study for breast cancer 01 trial J Clin Oncol 27 9 2009 1368 1374 [PubMed PMID: 19204202. Epub 2009/02/11.eng]
15. R.S. Kerbel Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer J Mammary Gland Biol Neoplasia 17 3-4 2012 229 239 [PubMed PMID: 23011602. Epub 2012/09/27.eng]
16. A. Maraveyas, T. Lam, J.W. Hetherington, and J. Greenman Can a rational design for metronomic chemotherapy dosing be devised? Br J Cancer 92 8 2005 1588 1590 [PubMed PMID: 15846302. Pubmed Central PMCID: 2362004]
17. J.A. Green, A.A. Dawson, L.F. Fell, and S. Murray Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease Br J Clin Pharmacol 9 5 1980 511 514 PubMed PMID: 6893156. Pubmed Central PMCID: PMC1429958. Epub 1980/05/01.eng
18. M.J. Dooley, S. Singh, and M. Michael Implications of dose rounding of chemotherapy to the nearest vial size Support Care Cancer 12 9 2004 653 656 [PubMed PMID: 14986078. Epub 2004/02/27.eng]
19. J.J. Sacco, J. Botten, F. Macbeth, A. Bagust, and P. Clark The average body surface area of adult cancer patients in the UK: a multicentre retrospective study PLoS One 5 1 2010 e8933 [PubMed PMID: 20126669. Pubmed Central PMCID: PMC2812484. Epub 2010/02/04.eng]
20. W. Bank World development indicators 2012 2012 World Bank Publications
21. B.A. Chabner, and T.G. Roberts Jr. Timeline: chemotherapy and the war on cancer Nat Rev Cancer 5 1 2005 65 72 [PubMed PMID: 15630416 ]
22. K.D. Miller, C.J. Sweeney, and G.W. Sledge Jr. Redefining the target: chemotherapeutics as antiangiogenics J Clin Oncol 19 4 2001 1195 1206
23. N.J. Vogelzang Continuous infusion chemotherapy: a critical review J Clin Oncol 2 11 1984 1289 1304
24. B.A. Kamen Metronomic therapy: it makes sense and is patient friendly J Pediatr Hematol Oncol 27 11 2005 571 572
25. A.F. Sobrero, C. Aschele, and J.R. Bertino Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation J Clin Oncol 15 1 1997 368 381
26. P. Hahnfeldt, J. Folkman, and L. Hlatky Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis J Theor Biol 220 4 2003 545 554 [PubMed PMID: 12623285 ]
27. Y. Shaked, U. Emmenegger, and S. Man Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity Blood 106 9 2005 3058 3061 [PubMed PMID: 15998832. Pubmed Central PMCID: 1895327. Epub 2005/07/07.eng]
28. F. Bertolini, P. Mancuso, Y. Shaked, and R.S. Kerbel Molecular and cellular biomarkers for angiogenesis in clinical oncology Drug Discov Today 12 19-20 2007 806 812 [PubMed PMID: 17933680 ]
29. Y. Takahashi, M. Mai, N. Sawabu, and K. Nishioka A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer Pancreas 30 3 2005 206 210 [PubMed PMID: 15782095 ]
30. X. Zhu, S. Wu, W.L. Dahut, and C.R. Parikh Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 2 2007 186 193 [PubMed PMID: 17261421 ]
31. S. Ederhy, H. Izzedine, and C. Massard Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists Crit Rev Oncol Hematol 80 3 2011 369 379 [PubMed PMID: 21330149 ]
32. G. des Guetz, B. Uzzan, K. Chouahnia, and J.F. Morere Cardiovascular toxicity of anti-angiogenic drugs Target Oncol 6 4 2011 197 202
33. S.P. Ivy, J.Y. Wick, and B.M. Kaufman An overview of small-molecule inhibitors of VEGFR signaling Nat Rev Clin Oncol 6 10 2009 569 579 [PubMed PMID: 19736552. Epub 2009/09/09.eng]
34. V. Ranpura, S. Hapani, and S. Wu Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis JAMA 305 5 2011 487 494 [PubMed PMID: 21285426. Epub 2011/02/03.eng]
35. S.N. Gardner A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs Cancer Res 60 5 2000 1417 1425 [PubMed PMID: 10728708 ]
36. J.R. Perry, K. Belanger, and W.P. Mason Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study J Clin Oncol 28 12 2010 2051 2057 [PubMed PMID: 20308655. Epub 2010/03/24.eng]
37. N.J. Meropol, D. Schrag, and T.J. Smith American society of clinical oncology guidance statement: the cost of cancer care J Clin Oncol 27 23 2009 3868 3874 [PubMed PMID: 19581533. Epub 2009/07/08.eng]